Is it too late to buy CSL Limited shares?

The CSL Limited (ASX:CSL) share price is up 32% this year. Is it too late to snap up shares?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has been one of the best performers on the local share market this year.

As of yesterday's close, the biotherapeutics company's shares had put on a year-to-date gain of 32%.

Is it too late to invest in CSL?

I don't think it is. While it is no longer the bargain buy it was at the start of the year, I still see a lot of value in its shares today.

Based on its FY 2018 forecast for net profit after tax in the range of US$1,480 million to US$1,550 million, I estimate it shares to be changing hands at approximately 30x forward earnings at present.

I think this is reasonable given its high quality business and strong long-term growth prospects.

With demand for its immunoglobulin and specialty products growing strongly, the recent approval of its Haegarda product, its fledgling Seqirus influenza business close to being profitable, and margins expanding, I believe CSL has the potential to deliver above-average earnings growth for the next decade.

I'm not alone in thinking this way. Last week analysts from the equities desk at Macquarie initiated coverage on CSL with an outperform rating and $146 price target.

This price target implies potential upside of over 10% from the last close price.

According to the note, the broker expects opportunities in hereditary angioedema and haemophilia to be the driver of strong earnings growth over the next few years.

I agree with this view and believe it makes CSL one of the best buy and hold investment options in the healthcare sector alongside the likes of Ramsay Health Care Limited (ASX: RHC) and Nanosonics Ltd. (ASX: NAN).

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of Nanosonics Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »